Christian Niedworok1, Frank vom Dorp1, Stephan Tschirdewahn1, Herbert Rübben1, Henning Reis2, Miklos Szucs3, Tibor Szarvas4,5. 1. Department of Urology, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. 2. Institute of Pathology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany. 3. Department of Urology, Semmelweis University, Budapest, Hungary. 4. Department of Urology, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. sztibusz@gmail.com. 5. Department of Urology, Semmelweis University, Budapest, Hungary. sztibusz@gmail.com.
Abstract
PURPOSE: Despite encouraging results in other cancers, in renal cell cancer, no consensus exists regarding the diagnostic and prognostic relevance of MMP-7. The aim of this study was to assess the diagnostic and prognostic potential of serum MMP-7 levels in renal cell cancer. Furthermore, parallel to the widely used ELISA method, we tested a new, fluid-phase, fluorescent immunoassay (B.R.A.H.M.S KRYPTOR®) for the quantitation of MMP-7. METHODS: We analyzed the serum samples of 174 individuals (77 patients and 97 age-matched healthy controls) by a commercially available sandwich ELISA and by a novel, automated, fluid-phase immunofluorescent assay (B.R.A.H.M.S KRYPTOR®). Results were correlated with the clinicopathological and follow-up data. RESULTS: MMP-7 concentrations showed a high concordance level (R (2) = 0.979) between the two methods (p < 0.001). Serum MMP-7 concentrations were significantly higher in patients compared to controls. At a cutoff value of 3.15 ng/ml, a specificity and a sensitivity of 70 and 82 % for the detection of RCC was found. Patients with metastasis had significantly higher MMP-7 levels as those without metastasis (p = 0.038 by KRYPTOR, p = 0.011 by ELISA). High MMP-7 levels proved to be independently associated with shorter overall, disease-specific and metastasis-free survival, regardless of the analytical method. CONCLUSIONS: Based on these results, serum MMP-7 levels have both diagnostic and prognostic potential. The KRYPTOR method provided comparable results to the standard ELISA analysis, with a high concordance level and can therefore be considered as a surrogate method. Its flexibility and automated operation make the KRYPTOR MMP-7 assay suitable for routine laboratory use in the daily practice.
PURPOSE: Despite encouraging results in other cancers, in renal cell cancer, no consensus exists regarding the diagnostic and prognostic relevance of MMP-7. The aim of this study was to assess the diagnostic and prognostic potential of serum MMP-7 levels in renal cell cancer. Furthermore, parallel to the widely used ELISA method, we tested a new, fluid-phase, fluorescent immunoassay (B.R.A.H.M.S KRYPTOR®) for the quantitation of MMP-7. METHODS: We analyzed the serum samples of 174 individuals (77 patients and 97 age-matched healthy controls) by a commercially available sandwich ELISA and by a novel, automated, fluid-phase immunofluorescent assay (B.R.A.H.M.S KRYPTOR®). Results were correlated with the clinicopathological and follow-up data. RESULTS:MMP-7 concentrations showed a high concordance level (R (2) = 0.979) between the two methods (p < 0.001). Serum MMP-7 concentrations were significantly higher in patients compared to controls. At a cutoff value of 3.15 ng/ml, a specificity and a sensitivity of 70 and 82 % for the detection of RCC was found. Patients with metastasis had significantly higher MMP-7 levels as those without metastasis (p = 0.038 by KRYPTOR, p = 0.011 by ELISA). High MMP-7 levels proved to be independently associated with shorter overall, disease-specific and metastasis-free survival, regardless of the analytical method. CONCLUSIONS: Based on these results, serum MMP-7 levels have both diagnostic and prognostic potential. The KRYPTOR method provided comparable results to the standard ELISA analysis, with a high concordance level and can therefore be considered as a surrogate method. Its flexibility and automated operation make the KRYPTOR MMP-7 assay suitable for routine laboratory use in the daily practice.
Entities:
Keywords:
KRYPTOR; MMP-7; Metastasis; Prognosis; Renal cell cancer
Authors: Tibor Szarvas; Markus Becker; Frank vom Dorp; Carolin Gethmann; Martin Tötsch; Agnes Bánkfalvi; Kurt W Schmid; Imre Romics; Herbert Rübben; Süleyman Ergün Journal: Cancer Sci Date: 2010-01-20 Impact factor: 6.716
Authors: Tibor Szarvas; Tobias Jäger; Markus Becker; Stephan Tschirdewahn; Christian Niedworok; Ilona Kovalszky; Herbert Rübben; Süleyman Ergün; Frank vom Dorp Journal: Pathol Oncol Res Date: 2011-01-21 Impact factor: 3.201
Authors: Azizbek Ramankulov; Michael Lein; Manfred Johannsen; Mark Schrader; Kurt Miller; Klaus Jung Journal: Cancer Sci Date: 2008-04-14 Impact factor: 6.716
Authors: Marianna Sabatino; Seunghee Kim-Schulze; Monica C Panelli; David Stroncek; Ena Wang; Bret Taback; Dae Won Kim; Gail Deraffele; Zoltan Pos; Francesco M Marincola; Howard L Kaufman Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Alejandro Martínez-Fernandez; Xabier García-Albeniz; Estela Pineda; Laura Visa; Rosa Gallego; Jordi Codony-Servat; Josep Maria Augé; Raquel Longarón; Pere Gascón; Antonio Lacy; Antoni Castells; Joan Maurel Journal: Ann Surg Oncol Date: 2009-03-04 Impact factor: 5.344
Authors: Christian Niedworok; Stephan Tschirdewahn; Henning Reis; Nils Lehmann; Miklós Szücs; Péter Nyirády; Imre Romics; Herbert Rübben; Tibor Szarvas Journal: Pathol Oncol Res Date: 2016-12-23 Impact factor: 3.201
Authors: T Szarvas; B Jardin-Watelet; N Bourgoin; M J Hoffmann; P Nyirády; C Oláh; T Széll; A Csizmarik; B Hadaschik; H Reis Journal: Endocr Connect Date: 2019-05-01 Impact factor: 3.335